Swing Therapeutics, a San Francisco, CA-based digital therapeutics company, raised $10.3M in Series A funding.
The round was led by Jazz Venture Partners with participation from Alumni Ventures, AME Cloud Ventures, Asahi Kasei Corporate Ventures, Gaingels, Kicker Ventures, Mana Ventures, and Metrodora Ventures.
The company intends to use the funds to support the execution of the PROSPER-FM randomized clinical trial and to launch an affiliated telemedicine clinic.
Led by CEO Mike Rosenbluth, Swing Therapeutics is developing digital treatments and services in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor.
The company received FDA Breakthrough Device Designation for its digital therapy for fibromyalgia management. Its near-term goal is to validate its digital therapy and bring it to market as an FDA-cleared, prescription digital therapeutic.
The PROSPER-FM study is investigating the effectiveness of two treatments for fibromyalgia: Digital Acceptance and Commitment Therapy (ACT), a form of cognitive behavioral therapy; and a Digital Symptom Tracker. Swing’s Digital ACT program is a daily-use digital therapeutic that includes engaging lessons and interactive exercises that help patients apply ACT principles to their unique circumstances and improve the ability to manage their condition over time. Swing’s Digital Symptom Tracker is a daily use digital therapeutic that includes common pain management approaches including monitoring daily symptoms over time and access to fibromyalgia and general health education.